Tascit

Quick links to important sections

Tascit

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tascit

What is Tascit? Overview

Property Description
Active ingredient Potassium Citrate (Monohydrate)
Form Extended-Release Tablet
Pharmacological class Urinary Alkalinizing Agent
Common purpose Modifies urine chemistry to improve solubility
Origin Synthetic (Potassium salt of citric acid)

What Type of Medicine is Tascit (Potassium Citrate)?

Tascit is a prescription-only medication with Potassium Citrate as its active pharmaceutical ingredient, classified as a Urinary Alkalinizing Agent. This medication belongs to a pharmacological class of agents specifically designed to modulate the chemical environment within the urinary system. The term Urinary Alkalinizing Agent signifies the drug's primary action of raising the urinary pH, a function used in managing acid-base balance. Tascit is considered a single-entity product, containing only Potassium Citrate as the main active therapeutic compound.


Tascit's Composition and Extended-Release Form

The core active ingredient is Potassium Citrate Monohydrate, a synthesized chemical compound that is a potassium salt of citric acid, giving the product a synthetic origin. Tascit is supplied as an Extended-Release Tablet for oral administration, a formulation designed to ensure sustained therapeutic action. The extended-release design is key, engineered to gradually release the active ingredient over a prolonged period. This sustained-release mechanism is necessary for consistent delivery, which is required for stable management of the body's acid-base balance.


General Principle: How Does Tascit Influence Urine?

Tascit's general principle of action is rooted in its ability to increase the pH of the urine. After the citrate component is absorbed, it is metabolized, leading to an increase in the excretion of bicarbonate ions by the kidneys. This process makes the urine significantly less acidic, a state known as alkalinization. This oral administration method effectively modifies the urine environment, where citrate complexes help reduce the spontaneous crystallization of certain materials. The drug's benefit lies in altering the properties of urine to make it less susceptible to solid formation, thereby promoting better solubility.

Regulatory References

  1. Potassium Citrate Labeling (DailyMed/NIH)

What side effects are possible with Tascit?

Possible Side Effects and Safety Information

This section describes the officially documented adverse effects and safety characteristics of Tascit (Potassium Citrate, Extended-Release Tablet) as reported in government regulatory documents.


Officially Documented Adverse Reactions

Adverse reactions are primarily associated with the gastrointestinal system and may be lessened by taking the medication with food.

System-Organ Class Common Adverse Reactions (Frequency Not Specified)
Gastrointestinal Disorders Abdominal discomfort, Nausea, Vomiting, Diarrhea, Loose bowel movements

Serious Safety Risks and Contraindications

Regulatory warnings highlight a risk of severe, clinically significant adverse events:

  • Hyperkalemia: A rapid and potentially fatal increase in serum potassium, which may be asymptomatic and can lead to cardiac arrest. This risk requires periodic laboratory monitoring.
  • Gastrointestinal Lesions: Solid oral potassium dosage forms, including extended-release tablets, have been associated with the development of ulcerative and stenotic lesions, obstruction, hemorrhage, or perforation in the gastrointestinal tract.
  • Contraindications: Tascit is restricted from use in patients with conditions that impair potassium excretion (e.g., chronic renal failure, severe myocardial damage) or conditions that cause a delay in tablet passage through the gut (e.g., peptic ulcer disease, delayed gastric emptying).

Population-Specific Safety Statements

  • Pediatric Use: The safety and effectiveness of Potassium Citrate have not been established in pediatric patients.
  • Pregnancy/Lactation: The drug is assigned Pregnancy Category C; use during pregnancy or lactation is advised only if clearly needed, as the effects on the fetus or breast milk are not fully known.
  • Drug Interactions: The label strictly cautions against concomitant use with potassium-sparing diuretics (such as triamterene or spironolactone) due to the risk of severe hyperkalemia.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Tascit (Potassium Citrate) can result in hyperkalemia, a life-threatening elevation of serum potassium levels. This condition is considered a medical emergency as lethal serum concentrations can be reached rapidly.

Documented Manifestations and Consequences

The most serious risk associated with hyperkalemia is cardiotoxicity, which can lead to cardiac arrest. Signs of severe toxicity are often detected through changes on an electrocardiogram (ECG), including tall, peaked T waves and the widening of the QRS complex. Physical symptoms documented in regulatory sources may include generalized weakness, mental confusion, and paresthesias (tingling or numbness) of the extremities.

Seeking Urgent Medical Attention

Immediate medical treatment is required upon the detection of hyperkalemia. The administration of Tascit must be discontinued at once. Emergency medical personnel will typically initiate specific supportive measures to stabilize the heart and reduce serum potassium. These measures, outlined in official prescribing information, may include the use of intravenous Calcium Gluconate to protect the heart, or the administration of Glucose with Insulin to shift potassium into cells. Patients with impaired potassium excretory mechanisms, such as renal dysfunction, are at a significantly higher risk for developing severe hyperkalemia following an overdose.

Therapeutic Uses of Tascit

Tascit is commonly used for chronic management of specific conditions in the urinary tract, and the medication is applied in addressing three primary indications: Hypocitraturic calcium oxalate nephrolithiasis, Renal Tubular Acidosis (RTA) with calcium stones, and Uric acid lithiasis.

In these chronic scenarios, Tascit supports a reduction in the rate of stone recurrence and assists in managing the overall disease burden. Addressing conditions marked by increased physiological stress contributes to easing the overall symptom load. For patients with uric acid stones, the therapy plays a role in managing the potential dissolution of existing small calculi.

“This intervention is applied in addressing symptoms related to systemic imbalance, which contributes to easing the physiological strain linked to systemic imbalance.”

Quick Fact: Support for Recurrent Nephrolithiasis Tascit helps maintain a sense of stability, and assists with managing symptoms associated with the chronic, recurrent nature of kidney stone disease.

Regulatory References

  1. FDA-Approved Prescribing Information for Potassium Citrate

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Tascit (Potassium Citrate) — Official Regulatory Information


Populations that Must Not Use (Contraindicated)

Use of Tascit is contraindicated in patients with a medical history of:

  • Hyperkalemia (high potassium levels) or conditions that predispose to it, such as chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, or adrenal insufficiency. This is due to the risk of severe hyperkalemia and cardiac complications.
  • Any condition causing arrest or delay in tablet passage through the gastrointestinal (GI) tract, including intestinal obstruction or delayed gastric emptying.
  • Active peptic ulcer disease or an active urinary tract infection.
  • Renal insufficiency with a glomerular filtration rate (GFR) less than 0.7 ml/kg/min.
  • Concomitant use with potassium-sparing diuretics (e.g., spironolactone, triamterene) is also contraindicated.

Populations with Restricted or Undetermined Use

  • Pediatric Use: Safety and effectiveness in children have not been established.
  • Pregnancy and Lactation: Tascit is classified as Pregnancy Category C. It should be given to a pregnant or breastfeeding woman only if clearly needed, as the potential effect on the fetus or infant is unknown.

What should I know about interactions with other medicines?

Tascit’s interaction profile is significantly structured by its reliance on the Cytochrome P450 3A4 (CYP3A4) enzyme for metabolism, as well as the P-glycoprotein (P-gp) transporter. Co-administration with other medicines that affect these systems can lead to clinically relevant changes in the plasma concentration of Tascit.

Strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, and ritonavir) or strong P-gp inhibitors substantially increase Tascit concentrations, which is classified by regulatory agencies as an interaction that may be contraindicated or require significant dose reduction and close monitoring. Conversely, co-administration with strong CYP3A4 inducers (such as rifampicin, phenytoin) lowers Tascit concentrations, potentially resulting in loss of efficacy, and is generally to be avoided.

Other Specific Interactions

Interacting Product Category Example Agents Listed Regulatory Requirement/Constraint
HMG-CoA Reductase Inhibitors (Statins) Simvastatin, Atorvastatin Increased risk of muscle toxicity (myopathy); may require Statin dose limitation or switching.
Anticoagulants Warfarin May alter the anticoagulant effect; requires frequent monitoring of International Normalized Ratio (INR).
Food/Beverages Grapefruit, Grapefruit Juice Must be avoided due to potent inhibition of intestinal CYP3A4, leading to increased Tascit exposure.

Mechanism of Action

How Tascit Works

The mechanism of Tascit (Potassium Citrate) is strictly pharmacodynamic, centered on a metabolic conversion and chemical interaction that alters the physiochemistry of the urinary system. The initial step is systemic, where the absorbed citrate ion acts as a metabolic precursor, primarily in the liver. Its metabolism generates bicarbonate ( HCO3^-), which introduces a systemic alkaline load. The kidney then manages this load, leading to a critical physiological effect: an increase in urinary pH (alkalinization).


Renal Pathway Modulation and Citrate Enhancement

The systemic alkaline load influences the renal tubular cells, reducing the reabsorption of the body's own endogenous citrate from the filtrate. This physiological modulation leads to an increase in the concentration of citrate in the urine, a condition known as citraturia. This action increases the concentration of citrate available for subsequent chemical interaction.


Physiochemical Chelation and Solubility Control

The excreted, highly concentrated citrate ions act as chelators within the urine, forming highly soluble complexes with free calcium ions ( Ca^2+). This dual action—reducing free calcium and raising pH—reduces the supersaturation of certain compounds and decreases the chemical potential for solid-phase transition in the urinary fluid.

Dosage and Administration Information

How Tascit (Potassium Citrate Extended-Release) is Used

Tascit is administered orally as an Extended-Release Tablet, the only approved route for this formulation. The tablets are designed to be swallowed whole and must not be crushed, chewed, or sucked, as doing so disrupts the extended-release mechanism and may cause mucosal irritation. The inert wax matrix that releases the medication is not absorbed and may be noticed in the stool.


Official Dosing and Frequency

The dosage is highly specific and depends on the patient's pre-treatment urinary citrate levels. The primary goal of therapy is to adjust the dose to achieve a urinary pH between 6.0 and 7.0 and a urinary citrate concentration greater than 320 mg/day.

Condition (Pre-treatment Citrate) Initial Daily Dose Frequency Pattern
Severe Hypocitraturia (<150 mg/day) 60 mEq Divided into 2 or 3 doses
Mild to Moderate Hypocitraturia (>150 mg/day) 30 mEq Divided into 2 or 3 doses

All doses must be taken with meals or within 30 minutes after meals or a bedtime snack to minimize gastrointestinal effects. The dosage may be titrated by a healthcare provider based on periodic 24-hour urinary chemistry measurements, but the dose must not exceed 100 mEq per day.


Administration Context and Constraints

Its use is intended as long-term maintenance therapy and requires concurrent lifestyle changes, including adherence to a high fluid intake (to achieve a urine volume of at least 2 liters per day) and salt limitation. Safety and effectiveness have not been established for use in the pediatric population. The medicine is contraindicated in patients with severe renal insufficiency.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tascit


Evidence for Use in Hypocitraturic Calcium Oxalate Nephrolithiasis

Research exploring the use of Tascit in individuals with recurrent kidney stones and low levels of citrate in their urine (hypocitraturia) includes both controlled clinical trials and long-term observational cohort studies. These studies primarily focused on adult populations with a history of recurrent stone events. The outcomes researchers monitored included the frequency of new stone formation (stone recurrence rate) and measurements of chemical shifts in the urine, such as increases in urinary pH and citrate concentration.

Studies reported patterns where the measured stone recurrence rate in the study group differed from control or placebo groups over follow-up periods. Researchers also described that participants exhibited measured increases in urinary pH and urinary citrate levels throughout the observation periods, aligned with the study protocols. Long-term outcomes extending well beyond four years are not fully established across all trials, and long-term patient adherence was noted as a factor influencing observational study patterns.


Evidence for Use in Renal Tubular Acidosis (RTA) with Calcium Stones

Research in this area was conducted using clinical studies and small-cohort interventional trials focusing on patients with distal Renal Tubular Acidosis (RTA) who also developed calcium stones. The main outcomes that were studied for this population included the rate of recurrent stone formation and measurements related to systemic acid-base balance. Sample sizes were modest in some clinical cohorts, which requires careful interpretation.

Findings describe patterns where the measured stone recurrence rate in the RTA-specific cohorts differed from control or baseline periods during observation. There is limited information for long-term outcomes of RTA related to non-stone, systemic physiological changes, and comparative evidence is lacking in some areas.


Evidence for Use in Uric Acid Lithiasis (Stone Prevention and Dissolution)

Studies exploring the use of Tascit for uric acid stones include long-term trials and interventional studies specifically designed to explore stone dissolution. Researchers examined two key outcomes: the dissolution or size reduction of existing stones and the prevention of future recurrence. Studies reported instances of stone dissolution or size reduction when the measured alkaline urinary pH levels were within the target range. However, research has explored stone dissolution primarily in smaller uric acid stones, and long-term recurrence prevention data for periods exceeding five years is not fully established across all available literature.

Key Studies & References

  1. Label: POTASSIUM CITRATE tablet, extended release - DailyMed (FDA-Approved Prescribing Information)
  2. Oral Dissolution Therapy of Uric Acid Stones: A Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Tascit (FAQ)


Q: What should I do if I accidentally take too much Tascit?

A: Regulatory information notes that severe hyperkalemia (high potassium) may occur rapidly and can be dangerous, potentially leading to cardiac arrest. Symptoms that have been reported include muscle weakness, tingling, or an irregular heartbeat. In the event of suspected over-consumption, seeking emergency medical attention is necessary.


Q: Is Tascit safe to take long-term?

A: Official dosage guidance describes this medicine as intended for long-term maintenance therapy. Because of this, the official labeling requires patients to undergo periodic monitoring of serum electrolytes (potassium) and urinary chemistry throughout the treatment period as part of the monitoring required for long-term use.


Q: What should I tell my doctor before starting Tascit?

A: According to the official product information, disclosure is required if a patient has hyperkalemia (high potassium) or conditions that may cause it, such as chronic renal failure or uncontrolled diabetes. Other conditions listed as contraindications include peptic ulcer disease, an active urinary tract infection, or any condition that causes a delay in tablet passage through the gastrointestinal tract.


Q: Does Tascit interact with common over-the-counter cold medicines?

A: Regulatory warnings caution against co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which are sometimes found in common cold preparations. This is due to an increased risk of high potassium levels (hyperkalemia). Consulting the full interactions section provides information on which types of medicines to avoid.


Q: Can I take vitamins or supplements with Tascit?

A: Official regulatory documents strictly advise against concomitant use with potassium-sparing diuretics and caution against agents that may increase potassium levels. This includes certain nutritional supplements and other medications; the label requires monitoring for high potassium (hyperkalemia) when these agents are considered.


Q: What should I look out for as a potential allergic reaction to Tascit?

A: Official documents describe that signs of an allergic reaction may include skin rash, hives, or itching, as well as swelling of the face, tongue, or throat. More serious signs noted include severe dizziness or difficulty breathing.


Q: How quickly does Tascit start working?

A: The onset of the medicine's effect begins within the first hour after a single dose. Official studies indicate that the maximum therapeutic effect on citrate excretion (the main goal of treatment) is typically reached by the third day of continuous, scheduled treatment.


Q: How long do the effects of Tascit last in the body?

A: Official pharmacology information indicates that following a single dose, the desired rise in urinary citrate lasts for 12 hours. When the medicine is stopped, urinary citrate levels begin to decline toward the pre-treatment baseline on the first day.


Q: Does Tascit cause weight gain or loss?

A: Swelling or rapid weight gain is listed among the serious side effects that have been reported from use of this medication. This is a sign that may indicate hyperkalemia (high potassium) or another adverse effect that warrants medical attention.


Q: Can Tascit make you feel tired or dizzy?

A: Official adverse reaction reports include tiredness and weakness as noted side effects. Dizziness is also listed, and when severe, it may be a sign of high potassium levels (hyperkalemia) or other serious issues that may warrant medical evaluation.


Q: What happens if I miss a dose of Tascit?

A: Patient guidance provided in product information describes that if a dose is missed, it is typically taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the guidance describes that the missed dose is skipped to continue the regular schedule. Taking a double dose is generally advised against.


Q: Does Tascit affect blood pressure?

A: The medication is not indicated for the treatment of blood pressure. However, official labeling notes that concurrent use with certain blood pressure medications, such as ACE inhibitors and ARBs, may increase the risk of high potassium levels (hyperkalemia) and requires monitoring.


Q: Is it okay to drink alcohol while using Tascit?

A: Official warnings advise against the use of alcohol while taking this medication. This is because alcohol may potentially worsen the effects of certain underlying disease conditions, such as increasing dizziness.


Q: Can Tascit affect my ability to drive?

A: Serious side effects that have been reported, such as dizziness, confusion, or mental/mood changes, could potentially affect a person's ability to safely drive or operate heavy machinery.


Q: What happens if I stop taking Tascit suddenly?

A: Patient information cautions that if the medicine is stopped suddenly without the supervision of a healthcare provider, the underlying condition being treated may potentially become worse.


Q: Does Tascit interact with birth control pills?

A: Official interaction warnings indicate that this medicine may interact with some birth control pills, specifically those containing the progestin drospirenone. This combination carries an increased risk of high potassium levels (hyperkalemia).


Q: Does Tascit affect mood or cause anxiety?

A: Serious adverse effects reported, particularly those associated with high potassium levels (hyperkalemia), can include mental or mood changes such as confusion or restlessness, and also anxiety.


Q: Is Tascit a controlled substance?

A: Official U.S. regulatory labeling classifies Tascit (Potassium Citrate Extended-Release) as a non-scheduled medication, meaning it is not a federally controlled substance.


Q: Are there generic versions of Tascit available?

A: Yes, regulatory listings confirm that the original brand product, which received approval in 1985, now has several FDA-approved generic versions available from various manufacturers.


Q: Does Tascit cause any changes to skin or vision?

A: Changes to the skin, such as rash or hives, are noted as potential signs of an allergic reaction that requires medical attention. Tingling in the hands, feet, or around the mouth is also listed as a possible side effect of high potassium levels (hyperkalemia).


Q: Is Tascit a new drug, or has it been around for a while?

A: The active ingredient in this formulation, Potassium Citrate Extended-Release, received its initial U.S. FDA approval in 1985, indicating it has been available for a significant period.


Q: Can Tascit affect sleep patterns?

A: Research has examined the effects of potassium intake on sleep, noting potential changes in sleep consolidation and efficiency. However, the official product labeling does not list general sleep disturbance as a common or serious adverse reaction.

How should Tascit be stored and disposed of?

Official Storage and Disposal Guidelines

Regulatory agencies define specific conditions for storing and disposing of Tascit to maintain its stability and ensure public safety.

Storage Requirement Official Constraint
Temperature Store at controlled room temperature (e.g., 20 C to 25 C); Keep away from heat and do not freeze.
Environmental Protection Keep in the original, tightly closed container; Protect the medicine from moisture and direct light.
Accessibility Keep out of the sight and reach of children.
Stability Do not use outdated medicine past the expiry date listed on the packaging.
Disposal Dispose of unused or expired medicine in accordance with local requirements. Do not flush down the toilet unless specifically authorized on the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tascit found in:

A-Z Index: